Search

Your search keyword '"Bunya VY"' showing total 2 results
Start Over "Bunya VY" Topic johnson & johnson Publication Type News
2 results on '"Bunya VY"'

1. Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjogren's disease study

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Medical research, Medicine, Experimental, Autoimmunity, Diseases -- Care and treatment -- United States, Autoantibodies, Immunoglobulin G, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels [...]

Published
2024

2. Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjogren's disease

Subjects
Autoimmunity, Diseases -- Care and treatment -- United States, Autoantibodies, Adults, Pharmaceutical industry, Johnson & Johnson, United States. Food and Drug Administration
Abstract

The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results